TL;DR: MOTS-c is a 16-amino-acid mitochondrial-derived peptide that signals through AMPK to enhance cellular energy metabolism, insulin sensitivity, and exercise capacity. AOD-9604 is a human growth hormone fragment that stimulates lipolysis without growth-axis effects. Both produce modest weight effects but for very different reasons — MOTS-c is metabolic-cellular, AOD-9604 is fat-oxidation-specific. Often stacked.
TL;DR — quick comparison table
| Dimension | MOTS-c | AOD-9604 |
|---|---|---|
| Origin | Mitochondrial-encoded peptide (12S rRNA) | HGH fragment 177–191 |
| Mechanism | AMPK activation, cellular metabolic regulation | Lipolysis stimulation in adipocytes |
| Primary effect | Insulin sensitivity, exercise capacity, metabolic flexibility | Fat oxidation, modest weight reduction |
| Trial stage | Preclinical strong, early human studies | Phase 2 obesity (~2.6–3.5% weight loss) |
| Typical reference dose | 5–10 mg weekly (split) | 300 mcg daily |
| Common side effects | Minimal; mild injection-site reactions | Minimal; mild injection-site reactions |
| PH availability | Available; growing demand | Available; niche |
| Noki Labs price | ₱1,400 (10 mg) | ₱1,500 (2 mg) |
| Best for | Metabolic flexibility, athletic performance, longevity research | Lean recomposition, targeted fat oxidation |
How each peptide works (the science)
MOTS-c: mitochondrial-derived metabolic regulator
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene — a rare example of a peptide hormone of mitochondrial origin. It activates AMPK (5'-AMP-activated protein kinase), the cellular energy-sensor pathway, leading to increased glucose uptake, fatty-acid oxidation, and improved insulin sensitivity in skeletal muscle. Lee et al. (Cell Metabolism 2015) characterised the foundational mechanism.
The downstream effects: improved metabolic flexibility (the body's ability to switch between glucose and fat as fuel), enhanced exercise capacity in animal models, and emerging evidence of longevity and age-related metabolic benefit.
AOD-9604: HGH fragment, fat-oxidation focus
AOD-9604 corresponds to amino acids 177–191 of human growth hormone — retaining HGH's lipolytic activity without IGF-1 elevation or anabolic signaling. It activates beta-adrenergic-like pathways in adipocytes, increasing fat oxidation, particularly during fasting. The mechanism is fat-specific; it does not meaningfully change cellular energy regulation more broadly.
Clinical evidence — head to head
MOTS-c: Lee et al. (Cell Metabolism 2015) demonstrated MOTS-c administration reversed diet-induced obesity and insulin resistance in mouse models. Reynolds et al. (2021) extended findings into human exercise-capacity and metabolic-flexibility outcomes.
AOD-9604: Heffernan et al. (PubMed 2001) characterised the lipolytic mechanism. Phase-2 obesity trials reported 2.6–3.5% weight loss over 12 weeks at 1 mg daily. Development was discontinued after these efficacy ceilings.
The peptides aren't really competing on the same axis. MOTS-c's signature is metabolic regulation and exercise capacity; AOD-9604's signature is fat oxidation. Both have modest mono-effect on body weight.
Cost in the Philippines
| Protocol | Vials | Total cost |
|---|---|---|
| MOTS-c, 12-week protocol (5–10 mg/wk split) | ~6 vials (10 mg) | ~₱8,400 |
| AOD-9604, 12-week daily protocol | ~6 vials (2 mg) | ~₱9,000 |
Comparable cost per cycle. Apply BULK20 for orders over ₱15,000.
Side effects — what's different
Both are among the most well-tolerated peptides. MOTS-c: rare mild injection-site reactions; no GI burden, no glycaemic disruption (it improves glucose handling, not impairs it). AOD-9604: similar profile — occasional mild redness, rare GI. Neither carries clinically meaningful side-effect ceilings in published research.
Which is better for [persona/goal]?
If your focus is metabolic flexibility and exercise capacity
MOTS-c. The AMPK pathway is the central metabolic regulator; AOD-9604 doesn't engage it.
If your focus is targeted fat oxidation
AOD-9604. The lipolytic mechanism is more specific to adipocyte triglyceride mobilisation.
If you have insulin resistance markers
MOTS-c. Direct evidence on insulin-sensitivity improvement; AOD-9604 doesn't materially change insulin signaling.
If running an athletic-performance protocol
MOTS-c, often paired with recovery peptides like KPV or BPC-157.
If running a recomposition or lean-fat-loss protocol
Stack them. They don't pharmacologically conflict.
Combining them
MOTS-c + AOD-9604 is a common reference stack pairing: cellular metabolic regulation (AMPK) + adipocyte fat oxidation. Run MOTS-c at 10 mg/week split into 2 doses; AOD-9604 at 300 mcg daily, ideally pre-fasted-cardio if exercise is part of the protocol. Both have favourable side-effect profiles, so the stack does not double burden.
Where to buy in the Philippines
- MOTS-c 10 mg: /products/mots-c — ₱1,400
- AOD-9604 2 mg: /products/aod-9604 — ₱1,500
Browse the performance & recovery collection. Pillars at /pages/mots-c-philippines and /pages/aod-9604-philippines. See AOD-9604 vs the heavyweight at /pages/aod-9604-vs-tirzepatide. Manila customers, /pages/peptide-supplier-manila.
FAQ
Q: Is MOTS-c a fat burner? Indirectly — it improves metabolic flexibility, which supports fat utilization, but it isn't a direct lipolytic.
Q: Will AOD-9604 raise my IGF-1? No.
Q: Can I take both daily? MOTS-c is typically weekly; AOD-9604 is typically daily. They run on different schedules and stack cleanly.
Q: Which one helps insulin resistance? MOTS-c — direct evidence on insulin sensitivity.
Q: Are these available in the Philippines? Yes — Noki Labs ships nationwide. We strongly recommend consulting a licensed healthcare provider familiar with peptide protocols before starting.
Always consult a licensed healthcare provider before starting any new peptide or wellness regimen. Individual results vary. Statements about our products are educational and not intended to diagnose, treat, cure, or prevent any disease.
Last reviewed: May 2026 · Read more in our FAQ